NCI Sharpless reflects on his time at FDA: “The engine producing new cancer therapies and diagnostics is doing very well” December 06, 2019Vol.45 No.45By Matthew Bin Han Ong
LOWY: Paylines are dropping because NCI is drawing more applicants who would’ve previously gone elsewhere December 06, 2019Vol.45 No.45By Matthew Bin Han Ong
Drugs & Targets FDA takes second action under international collaboration, approving treatment option for CLL or SLL November 22, 2019Vol.45 No.44
Drugs & Targets FDA grants Q BioMed approval to manufacture non-opioid cancer palliation drug November 22, 2019Vol.45 No.44
Drugs & Targets FDA approves crizanlizumab-tmca for sickle cell disease November 22, 2019Vol.45 No.44
Drugs & Targets European Commission approves two regimens of Keytruda for front-line metastatic, unresectable HNSCC November 22, 2019Vol.45 No.44
Drugs & Targets European Commission grants marketing authorization for Darzalex + lenalidomide and dexamethasone in frontline MM November 22, 2019Vol.45 No.44
Drugs & Targets Japan grants approval of Myriad Genetics’ BRACAnalysis Diagnostic System for breast cancer patients November 22, 2019Vol.45 No.44
Clinical Roundup Care in a multidisciplinary prostate cancer clinic increases discussion of treatment options, adherence to guidelines November 22, 2019Vol.45 No.44
